Retinitis

(redirected from Cytomegalovirus retinitis)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Cytomegalovirus retinitis: Cytomegalovirus infection, Mycobacterium avium complex

retinitis

[‚ret·ən′īd·əs]
(medicine)
Inflammation of the retina.

Retinitis

 

inflammation of the retina, generally in both eyes. It results from purulent infection of the retinal vessels caused by sepsis, a purulent focus, tuberculosis or other infectious diseases, or poisoning. Retinitis is usually accompanied by inflammation of the choroid (chorioretinitis). A characteristic development is the appearance of scotomata, or areas of depressed vision within the visual field that correspond to the inflammatory focus in the fundus of the eye. If treatment is inadequate, the depression of vision becomes permanent. Treatment depends on the causative disease.

References in periodicals archive ?
Retinal detachment in AIDS-related cytomegalovirus retinitis.
Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.
Cytomegalovirus retinitis (CMVR) is the most frequent cause of visual loss in individuals with AIDS, and before availability of HAART in the USA approximately 30% of patients with AIDS developed CMVR.
Ganciclovir can be given intra-ocularly instead of intravenous and oral therapy to treat cytomegalovirus retinitis.
He is a Clinical Associate Professor of Ophthalmology at the University of Southern California and has worked on trials for age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis.
and internationally by Gilead; Tamiflu(TM) (oseltamivir phosphate) for the treatment and prevention of influenza A & B, marketed worldwide by Hoffmann-La Roche; Vistide(R) (cidofovir injection) for the treatment of cytomegalovirus retinitis in AIDS patients, marketed by Gilead in the United States and internationally by Pharmacia Corporation; and DaunoXome(R) (daunorubicin citrate liposome injection) for the treatment of AIDS-related Kaposi's Sarcoma, marketed worldwide by Gilead.
CDS has a strong history of developing drug delivery devices for the back of the eye, including one product for cytomegalovirus retinitis, a blinding eye disease primarily afflicting late-stage AIDS patients, and Retisert(TM), which was recently approved by the FDA to treat non-infectious uveitis affecting the posterior segment of the eye.
Antisense technology was validated in August 1998, as Isis Pharmaceuticals' drug for the treatment of cytomegalovirus retinitis, Vitravene(TM), was approved by the FDA.
Gilead's expertise has resulted in proprietary therapeutics for important viral diseases, including a currently available therapy for cytomegalovirus retinitis, and products in development to treat diseases caused by human immunodeficiency virus, hepatitis B virus and influenza virus.
Gilead's expertise has resulted in a pipeline of proprietary therapeutics for important viral diseases, including a currently available therapy for cytomegalovirus retinitis, and products in development to treat diseases caused by human immunodeficiency virus, hepatitis B virus and influenza virus.